This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Synox Therapeutics UK Limited. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Axel Mescheder: Innovator in Cancer Treatment
Introduction
Axel Mescheder is a notable inventor based in Dublin, Ireland. He has made significant contributions to the field of cancer treatment, particularly through his innovative work on antibody therapies.
Latest Patents
One of his key patents is titled "Dosages of emactuzumab." This invention relates to a treatment regime that includes an antibody or antigen-binding fragment capable of binding specifically to the colony stimulating factor-1 receptor (CSF-1R). It is designed for use in the treatment of tenosynovial giant cell tumor (TGCT) in a subject, along with associated uses and methods. Axel holds 1 patent in this area.
Career Highlights
Axel Mescheder is currently associated with Synox Therapeutics UK Limited, where he continues to advance his research and development efforts in innovative cancer therapies. His work is pivotal in the ongoing fight against cancer, particularly in targeting specific receptors to improve treatment outcomes.
Collaborations
He collaborates with esteemed colleagues such as Raymond Barlow and Michael Cannarile, contributing to a dynamic research environment focused on groundbreaking medical advancements.
Conclusion
Axel Mescheder's contributions to cancer treatment through his innovative patent demonstrate his commitment to improving patient care and advancing medical science. His work continues to inspire future innovations in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile